Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer
Abstract
Background We previously conducted a genome-wide linkage analysis of Japanese nuclear families affected with prostate cancer and showed that the susceptibility to prostate cancer was closely linked to D8S550 at 8p23. The role of farnesyl diphosphate farnesyltransferase (FDFT1), which is located under the peak marker D8S550 at 8p23, and squalene synthase, the enzyme encoded by FDFT1, in prostate cancer was studied.Methods The association among common variants of FDFT1 with prostate cancer risk, the promoter activities of FDFT1 with different genotypes and the effects of inhibition of squalene synthase were studied, and the FDFT1 transcript levels of human prostate samples were quantified.Results The A allele of rs2645429 was significantly associated with prostate cancer risk in a Japanese familial prostate cancer population. Rs2645429 was located in the promoter region of FDFT1, and the AA genotype showed significantly increased promoter activity. The knockdown of FDFT1 mRNA expression or squalene synthase inhibition led to a significant decrease in prostate cancer cell proliferation. Additionally, human prostate cancer specimens expressed significantly higher levels of FDFT1 mRNA compared with noncancerous specimens. Finally, aggressive cancers showed higher transcript levels.Conclusions FDFT1 and its encoded enzyme, squalene synthase, may play an important role in prostate cancer development and its aggressive phenotypes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increased FDFT1 transcription is associated with increased invasion in prostate cancer.
“Although increased FDFT1 transcription is associated with increased invasion in prostate cancer, the exact role of FDFT1 in CRC progression has not been investigated35.”
From RETRACTED ARTICLE: Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression (2020) · cites this paper as [35]
The exact role of FDFT1 in CRC progression has not been investigated.
“Although increased FDFT1 transcription is associated with increased invasion in prostate cancer, the exact role of FDFT1 in CRC progression has not been investigated35.”
From RETRACTED ARTICLE: Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression (2020) · cites this paper as [35]
FDFT1 has seldom been studied in cancer research; limited studies addressed FDFT1 in prostate cancer, ovarian cancer, and lung cancer, but there is no information on the function of FDFT1 in CRC.
“Limited studies addressed FDFT1 in prostate cancer35, ovarian cancer46, and lung cancer47, but there is no information on the function of FDFT1 in CRC.”
From RETRACTED ARTICLE: Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression (2020) · cites this paper as [35]
The citation lists haven’t been fetched yet
References 47 · Cited by 39
- Authors
- Fukuma, Y., Matsui, H., Koike, H., Sekine, Y., Shechter, I., Ohtake, N., Nakata, S., Ito, K., & Suzuki, K.
- Affiliations
- Gunma University (JP)
- University of California, Los Angeles (US)
- Corresponding author
- Suzuki, K
- Venue
- Prostate Cancer and Prostatic Diseases
- Published
- 2012-05-01
- Volume
- 15
- Issue
- 4
- Pages
- 339-345
- ISSN
- 1365-7852 (ISSN-L)
- 1476-5608
- OpenAlex
- W2052091672
- Cited by
- 39
- References
- 47
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 6 · 2018: 6 · 2017: 3 · 2016: 3 · 2014: 2
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Prostate Cancer and Prostatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Keywords
- prostate cancer, squalene synthase, FDFT1, genetic susceptibility, promoter activity, tumor aggressiveness, tumor cell proliferation
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alleles, Genotype, Humans, Japan, Genetic Linkage, Male, Middle Aged, Neoplasm Invasiveness, Prostatic Neoplasms, Risk Factors, Farnesyl-Diphosphate Farnesyltransferase, Polymorphism, Single Nucleotide, Cell Line, Tumor, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
